New insulin GZR33 aims to improve diabetes control

NCT ID NCT07242664

Recruiting now Disease control Sponsor: Gan and Lee Pharmaceuticals, USA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new long-acting insulin called GZR33 in 12 adults with type 1 diabetes. The goal is to see how well it controls blood sugar compared to an existing insulin, degludec, and to check its safety. Participants will receive both insulins at different times to compare their effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR33 (a long-acting insulin)
What this could lead to: If successful, this could lead to a new long-acting insulin option for people with type 1 diabetes, potentially offering similar or better blood sugar control with fewer injections.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so results may not apply to everyone. The new insulin may not work as well as expected or could cause unexpected side effects like low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITIS

Contacts and locations

Locations

Profil
RECRUITING

Neuss, Germany
Profil Institut
RECRUITING

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.